Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
GRI BioGRI -1.16%33 PB Ratio is 0.26 as of Aug. 19, 2026. GuruFocus rates GRI with a GF Score™ of 33/100. The stock has 1 warning sign investors should review. Among 1,216 Biotechnology companies, GRI Bio ranks better than 97.37% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-08-19), GRI Bio's share price is $1.72. GRI Bio's Book Value per Share for the quarter that ended in Mar. 2026 was $6.65. Hence, GRI Bio's PB Ratio of today is 0.26.
The historical rank and industry rank for GRI Bio's PB Ratio or its related term are showing as below:
GRI'
s PB Ratio Range Over the Past 10 Years
Min: 0 Med: 0 Max: 0.26
Current: 0.26
During the past 5 years, GRI Bio's highest PB Ratio was 0.26. The lowest was 0.00. And the median was 0.00.
GRI's PB Ratio is ranked better than 97.37% of 1216
companies
in the Biotechnology industry
Industry Median: 2.895
vs GRI: 0.26
During the past 12 months, GRI Bio's average Book Value Per Share Growth Rate was -94.30% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
GRI Bio PB Ratio Related Terms
GRI Bio PB Ratio Historical Data
* Premium members only.
The historical data trend for GRI Bio's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, GRI Bio's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GRI Bio PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, GRI Bio's PB Ratio distribution charts can be found below:
* The bar in red indicates where GRI Bio's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
GRI Bio's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
GRI Bio (GRI) has a PB Ratio of 0.26 as of Aug. 19, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on GRI Bio and its competitors. According to the industry distribution chart, GRI Bio ranks #32 out of 1216 companies in the Biotechnology industry, placing it in the top 2.6%.
Is GRI Bio's PB Ratio too high?
GRI Bio's current PB Ratio is 0.26. The Biotechnology industry median PB Ratio is 2.90. GRI Bio's value of 0.26 is 91% below this industry median. Based on the distribution chart, GRI Bio ranks #32 out of 1216 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, GRI Bio has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does GRI Bio's PB Ratio compare to ISCO and VRAX?
According to the Biotechnology industry distribution chart, GRI Bio ranks #32 out of 1216 companies for PB Ratio. This places GRI Bio in the top 3% of its industry — outperforming the majority of peers. The industry median PB Ratio is 2.90. GRI Bio's value of 0.26 is 91% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.90, based on 1,216 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. GRI Bio's current PB Ratio of 0.26 is 91% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on GRI Bio and its competitors. For the Biotechnology industry, the median PB Ratio is 2.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GRI Bio's current PB Ratio is 0.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GRI Bio stock overvalued right now?
GRI Bio (GRI) has a current PB Ratio of 0.26. The current PB Ratio is 0.26 and 91% below the Biotechnology industry median of 2.90. GRI Bio's overall GF Score™ is 33/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For GRI Bio (GRI), the current PB Ratio is 0.26 as of Aug. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.
33GF Score
Get the complete analysis for GRI
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GRI has been successfully added to your 
